Advancing Care in Narcolepsy and Idiopathic Hypersomnia: Optimizing Treatment and Addressing Challenges in Sleep Management
 
 A continuing medical education and nursing continuing professional
development activity provided by NAMCP and AAMCN.

This activity is an archive from the live session from the 2024 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 1, 2025 to March 1, 2026
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Avadel CNS Pharmaceuticals, LLC and Jazz Pharmaceuticals

Description:
Hypersomnia is characterized by recurrent episodes of excessive daytime sleepiness or prolonged nighttime sleep. It may be caused by another sleep disorder (such as narcolepsy or obstructive sleep apnea), dysfunction of the autonomic nervous system, or drug or alcohol abuse. In some cases, it results from a physical problem, such as a tumor, head trauma, or injury to the central nervous system. Even when factors such as treatment adherence, medications, comorbid illness, and inadequate sleep duration are controlled, up to 33% of all Americans still experience some type of sleep-depravity. For most people, mild sleepiness is apparent only during boring, sedentary situations, however patients with narcolepsy, severe hypersomnia, can lead to involuntary somnolence during regular activities that could put the patient and others in a harmful situation, such as driving, eating, or talking. Idiopathic hypersomnia (IH) is a sleep disorder in which a person feels excessive tiredness, even after a full and uninterrupted night of sleep. People with this condition may sleep longer than normal, sometimes 11 or more hours a night, yet still feel tired during the day. It is important that medical directors, clinicians and healthcare professionals are kept up-to-date on the novel treatment strategies that will help address the challenges that patients are dealing with daily.

Upon completion of this activity, participants will be able to:

  • Explore the prevalence and burden of narcolepsy and idiopathic hypersomnia (IH) to assess the impact and risks associated with a patients’ quality of life and care management

  • Identify comprehensive strategies to address the needs of patients with narcolepsy and IH, including a focus on individualized diagnosis and treatment

  • Analyze the latest AASM guidelines and clinical data on the efficacy and safety of available and emerging therapies in improving outcomes for patients with narcolepsy and IH

  • Discuss the challenges surrounding appropriate care in patients with narcolepsy and how to overcomes those barriers, including using resources and updates from AHA’s Life’s Essential 8 on healthy sleep

  • Assess managed care strategies that help close the gaps in access to new and emerging therapies for narcolepsy and IH to provide optimal cost management and improved outcomes
     

Faculty:
Clete A. Kushida, MD, PhD, FAASM
Division Chief and Medical Director, Stanford Sleep Medicine
Associate Chair-Sleep Medicine, Department of Psychiatry and Behavioral Sciences
Professor, Department of Psychiatry and Behavioral Sciences,
Stanford University Medical Center
clete@stanford.edu

Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.

Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Kushida has served as a consultant for Alkermes, Asleep, Avadel Pharmaceuticals, Cerebra Health, Genentech, Koko Home, Lilly, Morgan Stanley Australia, Oxama Medical, Restful Robotics, Samsung, SoundHealth, Vivos Therapeutics. All relevant financial relationships have been mitigated.

Planning Committee Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship with an ineligible company to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

NAMCP and/or this website do not provide medical advice, diagnosis, or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.

This activity is supported by educational grants from
Avadel CNS Pharmaceuticals, LLC and Jazz Pharmaceuticals


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue